Atlas Venture and Biogen Inc. are teaming up to finance a single-program start-up that will seek to address the unmet medical need of hereditary ataxias, a group of orphan genetic disorders that can diminish a patient’s basic motor skills, such as speech and walking.
The two joined forces to fund a $17 million Series A for Ataxion Inc